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Summary 
Background: Matrix-metalloproteinases (MMP) and cancer cell invasion are 
crucial for solid tumour metastasis. Important signalling events triggered by 
inflammatory cytokines, such as tumour necrosis factor α (TNFα), include Src-
kinase-dependent activation of Akt and focal adhesion kinase (FAK) as well as 
phosphorylation of caveolin-1. Based on previous studies where we demonstrated 
amide-type local anaesthetics block TNFα-induced Src activation in malignant cells, 
we hypothesised that local anaesthetics might also inhibit the 
activation/phosphorylation of Akt, FAK and caveolin-1, thus attenuating MMP release 
and invasion of malignant cells. 
Methods: NCI-H838 lung adenocarcinoma cells were incubated with 
ropivacaine or lidocaine (1 nM-100 µM) in absence/presence of TNFα (20 ng ml-1) 
for 20 minutes or 4 hours, respectively. Activation/phosphorylation of Akt, FAK and 
caveolin-1 were evaluated by Western blot, and MMP-9 secretion was determined by 
ELISA of cell culture supernatant. Tumour cell migration (electrical wound-healing 
assay) and invasion into Matrigel® were assessed as well. 
Results: Ropivacaine (1 nM-1 µM) and lidocaine (1-10 µM) significantly 
reduced TNFα-induced activation/phosphorylation of Akt, FAK and caveolin-1 in 
NCI-H838 cells. MMP-9 secretion triggered by TNFα was significantly attenuated by 
both lidocaine and ropivacaine (half-maximal inhibitory concentration [IC50]=3.29x10-
6 M for lidocaine; IC50=1.52x10-10 M for ropivacaine). TNFα-induced increase in 
invasion was completely blocked by both lidocaine (10 µM) and ropivacaine (1 µM).  
Conclusion: Ropivacaine and lidocaine – at clinically relevant concentrations – 
blocked tumour cell invasion and MMP-9 secretion by attenuating Src-dependent 
inflammatory signalling events. Although determined entirely in vitro, these findings 
  
provide significant insight into the potential mechanism by which amide-LAs might 
diminish metastasis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Introduction 
Conflicting evidence suggests anaesthesia technique delivered during cancer 
surgery may influence patient outcome.1 Retrospective analyses indicate the 
perioperative use of regional anaesthesia using amide-linked local anaesthetics 
(LAs) may decrease cancer recurrence and metastasis in these patients.2-4 Anti-
inflammatory effects of LAs in various epithelial and endothelial cell types are well 
known.5 6 The fact that LAs have anti-inflammatory properties in malignant cells lead 
to our recent observations that amide-type LAs inhibit the activation of inflammatory 
Src tyrosine protein kinase (Src), a critical mediator of endothelial hyperpermeability 
and also cancer cell extravasation and metastasis.7 8 
Matrix-metalloproteinases (MMPs) are important in the pathogenesis of new 
metastatic sites from solid tumours as these enzymes degrade the extracellular 
matrix and basal lamina, thus allowing malignant cells to enter or escape the primary 
tumour, enter the circulation, and extravasate to form satellite lesions.9 10 De novo 
synthesis of MMPs, e.g., due to stimulation with tumour necrosis factor α (TNFα), 
largely depends on Src-dependent activation of Akt and focal adhesion kinase (FAK) 
as well as phosphorylation of caveolin-1 (Cav-1) by Src,11 signalling pathways which 
are also required for cancer cell migration.12-14 
In the present study, we tested the hypothesis that amide-type local 
anaesthetics such as lidocaine and ropivacaine inhibit TNFα-induced Akt and FAK 
activation and Src-dependent Cav-1 phosphorylation, thus attenuating MMP-9 
secretion, migration, and invasion of lung adenocarcinoma cells (Figure 1).  
 
 
  
Material and Methods 
Cell culture 
Human NCI-H838 lung adenocarcinoma cells (CRL-5844, ATCC, Rockville, 
MD) were cultured as previously described.7 All cells were maintained in 5% CO2 
and 95% room air in a water-jacketed 37°C incubator. 
 
Experimental procedure 
NCI-H838 cell monolayers were incubated with TNFα (Gibco Invitrogen, 
Carlsbad, CA, final concentration 20 ng ml-1) in absence or presence of lidocaine 
(lidocaine-HCl 2%, APP Pharmaceuticals, Schaumburg, IL) or ropivacaine 
(Naropin® 0.5%, APP Pharmaceuticals) at concentrations ranging from 1 pM – 100 
µM, depending on the experiment. Incubation times varied between 20 minutes for 
Western blot analysis (Akt, FAK and Cav-1) and 4 hours for determination of MMP-9 
secretion. For some experiments, cells were pre-treated with wortmannin (100 nM, 
Sigma Aldrich, St. Louis, MO), an inhibitor of phosphoinositide-3 kinase (PI3K), 
which is required for the activation of Akt, or the specific FAK inhibitor FI 14 (5 µM, 
Tocris Bioscience, Minneapolis, MN). 
 
Cell harvest and lysis 
 After indicated incubation times, cells were harvested and lysed as described 
previously.15 Total protein concentration was determined using the DC Protein Assay 
Kit (BioRad, Hercules, CA) in accordance with the manufacturer’s instructions. 
Immunoglobulin G was used for the generation of a standard curve. 
 
Western blot analysis 
  
Whole cell lysates were subjected to Western blot analysis following a 
protocol previously published by Bakhshi et al.16 Antibodies against FAK, 
phosphorylated at tyrosine 397 (pY397), total FAK, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), and total Akt were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA), against phospho-tyrosine 14 (pY14) Cav-1, total 
Cav-1, and β-actin from BD Biosciences (Franklin Lakes, NJ), and for Akt, 
phosphorylated at threonine 308 (pT308), from Cell Signaling Technology (Danvers, 
MA).  
 
Enzyme-linked immunosorbent assay (ELISA) 
The concentration of MMP-9 in cell culture supernatant was determined using 
the human MMP-9 DuoSet from R&D Systems (Minneapolis, MN) in accordance with 
the manufacturer’s instructions. Total amount of MMP-9 secreted by the cells in each 
well was calculated from the ELISA values (pg ml-1) and normalized to the amount of 
protein (pg mg-1 protein) found in whole cell lysates. 
 
Electrical wound-healing assay 
NCI-H838 lung cancer cells were grown to confluence on gold-plated 
microelectrodes (ECIS cultureware; Applied Biophysics, Troy, NY) coated with 0.2 % 
gelatin (Sigma-Aldrich, St. Louis, MO). Electrical impedance measured over time 
across the monolayer at 1 V, 4,000 Hz with the Electric Cell-Substrate Impedance 
Sensing (ECIS) system (Applied Biophysics), was used to calculate transepithelial 
resistance. After an equilibration period of 30 minutes, TNFα (final concentration 20 
ng ml-1) was added in absence or presence of lidocaine (10 µM) or ropivacaine (1 
µM). After that, cells growing in the middle of the gold electrode, i.e. on the small 
  
active electrode, were injured via the application of 2.5 V at 40,000 Hz for 10 
seconds, leading to an immediate drop in transepithelial resistance.17 Recovery of 
transepithelial resistance after electrical injury was used as a surrogate for cell 
migration.17 For some experiments, cells were pre-treated for 30 minutes prior to the 
addition of TNFα with either wortmannin (100 nM) or FAK inhibitor (FI) 14 (5 µM). 
 
In vitro invasion assay  
 Transwell inserts with a polycarbonate membrane with 8 µm pore size 
(Falcon® Permeable Support, BD Biosciences) were coated with 20 µl of Matrigel® 
(Growth Factor Reduced, from Corning, Tewksbury MA). NCI-H838 cells were 
suspended in RPMI-1640 medium with 0% FBS and treated with either lidocaine (10 
µM) or ropivacaine (1 µM) in absence or presence of TNFα (20 ng ml-1). The cell 
suspension was inoculated in the upper chamber of the Transwell, which was then 
inserted into a 24-well cell culture plate (TPP Techno Plastic Products, Trasadingen, 
Switzerland). The bottom chamber of the system was pre-filled with RPMI-1640 
medium supplemented with 10% FBS as well as with the same experimental 
reagents (TNFα, LAs) found in each corresponding upper chamber. Cells were 
allowed to invade into the Matrigel-coated membrane for 6 hours. Non-invading cells 
were removed, invading cells were fixed with 2% paraformaldehyde solution 
(Kantonsapotheke Zurich, Zurich, Switzerland) and stained with 4',6-diamidino-2-
phenylindole (DAPI, Life Technologies, Zug, Switzerland). Membranes were 
mounted on glass slides for microscopy and quantitative image analysis.  Images 
were acquired at 20x magnification using a Leica DM6000B microscope equipped 
with a DFC350FX camera and Leica Application Suite Advanced Fluorescence 
software, Version 3.x for Windows (all from Leica Microsystems, Heerbrugg, 
  
Switzerland). Semi-automated counting of cell nuclei stained with DAPI was carried 
out using the ImageJ software, Version 1.47v for Mac (http://imagej.nih.gov/ij). Eight 
fields of view were quantified per slide and averaged for further analysis. 
 
Statistical analysis 
Normal distribution was assessed using a Shapiro–Wilk test. Normally 
distributed data of transepithelial resistance were analysed by one-way ANOVA. 
Non-normally distributed data (invasion) were analysed with non-parametric testing 
(Kruskal-Wallis and subsequent Mann-Whitney U tests) with post hoc corrections 
using the Simes-Hochberg method in order to keep the family-wise error rate below 
0.05. All other data were evaluated with two-way ANOVA with the local anaesthetic 
(or other treatments) and the absence or presence of TNFα as factors to be tested, 
whereas we report the F ratio with the degrees of freedom for each of these factors 
as well as for the interaction between them. Bonferroni post hoc testing was 
conducted to detect differences between groups. The exact number of experiments 
is indicated in the respective figure legend. All tests were performed two-sided and 
non-blinded using GraphPad Prism software for Mac, Version 6 (GraphPad 
Software). A p-value of less than 0.05 was considered statistically significant.  
The half-maximal inhibitory concentration (IC50)18 was assessed for lidocaine 
and ropivacaine on TNFα-induced MMP-9 secretion by NCI-H838 lung cancer cells 
by plotting the MMP-9 concentration against the (logarithmic) concentration of the 
local anaesthetic. Curve fitting (Hill slope fixed at −1.0) was conducted using non-
linear regression analysis with the following equation:  
Y=Bottom + (Top-Bottom) / (1+10^((X-LogIC50))) 
Results reported in Table 1 are values with 95% confidence interval (CI, for IC50, top, 
  
and bottom). 
  
  
Results 
Cytotoxic effects of local anaesthetics at the concentrations used were 
excluded in a previous study7.  
Representative Western blots of the activated form of Akt, phosphorylated at 
threonine 308 (pT308 Akt), total Akt, and GAPDH are shown in Figures 2A and 2B. 
Quantitative densitometry analysis revealed a 2.6-fold increase in Akt activation after 
treatment with TNFα alone compared to untreated cells (2.71 [SD 0.92], Figure 2Ci 
and 2.35 [0.45], Figure 2Cii), respectively. In the experiments involving lidocaine, 
analysis with two-way ANOVA showed a significant effect of TNFα (F(1,90)=17.55, 
p<0.001). Post hoc analysis revealed a significant reduction in TNFα-induced Akt 
activation in presence of lidocaine at a concentration of 1 µM (decrease of 36% 
[20%], p=0.03, Figure 2Ci). As shown in Figure 2Cii, TNFα-induced Akt activation 
was also significantly blocked by ropivacaine at 1 nM (by 40% [36%], p=0.03). 
The same samples were also evaluated for FAK phosphorylation at tyrosine 
397 (pY397 FAK) as compared to total amount of FAK protein (Figures 2D and 2E). 
We again observed a significant effect of TNFα on FAK phosphorylation in both sets 
of experiments (F(1,69)=15.81, p<0.001 for lidocaine experiments, Figure 2Fi; 
F(1,60)=23.14, p<0.001 for ropivacaine experiments, Figure 2Fii). The effect of the 
two different LAs reached statistical significance by two-way ANOVA (F(4,69)=4.07, 
p=0.005 for lidocaine experiments, Figure 2Fi; F(4,60)=9.36. Post hoc analysis was 
comparable to those observed with Akt: 10 µM lidocaine attenuated TNFα-induced 
FAK activation by 51% [25%] (p=0.04) and ropivacaine completely abolished the 
TNFα-induced increase in pY397 FAK at a concentration of 1 nM (p=0.01). At higher 
concentrations (beginning at 10 µM) and in absence of TNFα, ropivacaine 
  
significantly decreased FAK phosphorylation below baseline values (reduction of 
59±24%, p=0.01, Figure 2Fii). 
We also assessed the effect of lidocaine and ropivacaine on TNFα-induced 
Cav-1 phosphorylation at tyrosine 14 via Western blot (pY14 Cav-1, Figures 3A and 
3B). TNFα significantly increased pY14 Cav-1 by 75% [51%], (F(1,60)=4.22, p=0.04, 
Figure 3Ci) and 49% [36%] (F(1,65)=5.42, p=0.02, Figure 3Cii), respectively. It also 
became evident that both LAs completely blocked TNFα-induced Cav-1 
phosphorylation at concentrations of 1 µM (p=0.002 for lidocaine, p=0.004 for 
ropivacaine). 
 Non-linear curve fitting was used to determine IC50 values of lidocaine and 
ropivacaine on TNFα-induced MMP-9 secretion as shown in Table 1: the IC50 for 
lidocaine was 3.29 µM (95% CI, 1.36 µM – 7.98 µM) with a maximum effect of 62% 
(95% CI, 51% – 75%) whereas ropivacaine had a lower IC50 (152 pM, 95% CI, 42 
pM – 557 pM) lower maximum effect of 30% (95% CI, 17% – 42%, all Table 1). NCI-
H838 cells pre-treated with either wortmannin (100 nM) or FI 14 (5 µM) also showed 
a significant reduction in TNFα-induced MMP-9 secretion of 37% [7%] and 52% 
[5%], respectively (p<0.001 compared to TNFα alone for both, all Figure 4A).  
 
 Resistance values measured over NCI-H838 monolayers were normalized to 
baseline values and plotted against time as shown in Figure 4B. Treatment with 
TNFα resulted in complete restoration of monolayer integrity (4% [12%] of pre-
injured baseline resistance) compared to untreated cells in which the resistance was 
still 23% [13%] below basal at the 3 hour time point (Figure 4C; one-way ANOVA, 
p=0.006). Lidocaine and ropivacaine both completely abolished TNFα-induced 
migration and recovery of barrier properties (31% [12%] of basal in presence of 
  
lidocaine, p<0.001; 23% [8%] of basal in presence of ropivacaine, p=0.01) compared 
TNFα alone. Pre-treatment with either wortmannin or FI 14 also decreased the 
restoration of barrier properties compared to TNFα alone (43% [6%] for wortmannin, 
p<0.001; 42% [12%] for FI 14, p<0.001; Figure 4C). 
 
Supplemental Figure 1 shows representative microscopic images of 
Matrigel®-coated membranes after the invasion assay. Counting of the number of 
cells per field of view showed a significant increase in invasion when cells were 
stimulated with TNFα (median 125 [minimum – maximum 88 – 160] cells/field vs. 
control, 64 [53 – 71] cells/field, p<0.001, Figure 5). Incubation of the cells with 
ropivacaine or lidocaine alone did not alter the number of invading cells compared to 
unstimulated cells (data not shown). However, both lidocaine (10 µM) and 
ropivacaine (1 µM) completely blocked TNFα-induced invasion of tumour cells, 
similar to that observed in presence of wortmannin or FI 14 (p<0.01 vs. TNFα alone 
for all comparisons, Figure 5).  
  
Discussion 
In this study, we evaluated the effect of lidocaine and ropivacaine on TNFα-
induced, Src-dependent inflammatory signalling events in malignant cells, namely 
activation of Akt and FAK as well as phosphorylation of Cav-1.  
As hypothesised, these signalling events were blocked in presence of the 
amide-linked LAs. We then also linked inhibition of this inflammatory signalling 
downstream of TNFα and Src to function, assessing the effect of LAs on MMP-9 
production, migration, and invasion of H838 cells, further elucidating a potential 
mechanism by which local anaesthetics might be able to attenuate metastasis of 
solid epithelial tumours.  
Mechanisms similar to inflammatory processes may play an important role in 
the development, growth, and metastasis of solid tumours.21-23 We have previously 
shown that amide-linked local anaesthetics, such as lidocaine and ropivacaine, 
inhibit TNFα-induced activation of Src by blocking the early propagation of signalling 
at the level of TNFα receptor-1 (TNF-R1).7 8 Activated Src functions to increase 
vascular permeability,24 cancer and inflammatory cell adhesion to the endothelium, 
and cancer cell migration. Additionally, Src is involved in signalling epithelial-to-
mesenchymal transformation and extravasation of cancer cells, processes that are 
necessary for solid tumour metastasis.21 25  
The release of MMPs by neutrophils and malignant cells alike is known to 
contribute to tumour growth and metastasis by degrading the extracellular matrix and 
breaking up the basal lamina thereby enabling cancer cells to enter and then exit the 
circulation at a remote location.9 10 TNFα-induced expression of MMPs by malignant 
cells is Src-dependent and involves the PI3K/Akt pathway.11 Activation of Akt by 
PI3K is Src-dependent and involved in numerous downstream signalling events that 
  
contribute to cancer cell growth, proliferation and survival and has therefore become 
a very interesting protein for targeted therapies.26 The results of our study clearly 
show that both lidocaine and ropivacaine significantly inhibit Akt activation in NCI-
H838 non-small cell lung cancer (NSCLC) cells, thus attenuating MMP-9 production. 
Cav-1 is a primary Src substrate24 and Src-dependent Cav-1 Y14 
phosphorylation is important for migration of (malignant) cells via the regulation of 
focal adhesion dynamics and assembly,12 14 which also involves the PI3K/Akt 
pathway.27 pY14-Cav-1 promotes tumour growth whereas loss of Cav-1 expression 
in either the tumour microenvironment or cancer cells per se leads to a significant 
increase in invasiveness and overall worse prognosis.28-30 As we have previously 
shown that tyrosine phosphorylation of Cav-1 promotes its degradation,16 reduction 
of pY14 Cav-1 as seen in our study may be a mechanism by which the LAs reduce 
the metastatic potential of malignant cells. 
FAK is the most important kinase in focal adhesion signalling and its 
activation is not only PI3K- and Src-dependent,31 32 but also crucial for cell 
orientation, actin cytoskeletal assembly/re-organization, and ultimately cancer cell 
migration.12 13 33. The results from our study confirm these previous findings. We 
showed that enhanced cancer cell migration induced by TNFα was impaired by the 
PI3K inhibitor wortmannin, the specific FAK inhibitor FI 14, and importantly, lidocaine 
and ropivacaine had a similar effect. 
In order to combine findings on the effect of LAs on TNFα-signalling, 
migration, and MMP secretion, we assessed the impact of lidocaine and ropivacaine 
on tumour cell invasion into a collagen-rich environment in vitro. We demonstrated 
that the amide-linked local anaesthetics lidocaine and ropivacaine were able to 
completely mitigate TNFα-induced enhancement in invasion and showed that 
  
inhibition of Akt activation and FAK had the same effect. These findings are in 
accordance with results from experiments conducted by Baptista et al., where 
ropivacaine was also demonstrated to inhibit invasion of metastatic colon cancer 
cells (SW620) due to an inhibition of the Nav1.5 subset of voltage-gated sodium 
channels (VGSC).34 However, we previously showed that lidocaine and ropivacaine 
(amide-linked LAs), but not chloroprocaine (ester-type LA), inhibit TNFα-induced Src 
activation and downstream signalling in NCI-H838 lung cancer cells independent of 
VGSC blockade,7 further supporting our hypothesis that LAs exhibit anti-
inflammatory and anti-metastatic effects by blocking TNFα signalling at level of its 
receptor TNF-R1.8  
Taken together with results of PI3K inhibitor wortmannin and FAK inhibitor FI 
14, the observed attenuation of cancer cell invasion by lidocaine and ropivacaine is 
likely due to the blockade of Src-dependent Akt and FAK activation as well as of 
Cav-1 phosphorylation. 
In summary, cancer dissemination is a multi-step process where many cellular 
and molecular regulatory mechanisms may be targets for therapeutic interventions. 
This study clearly demonstrates the importance of the blockade of the Src pathway 
by clinically relevant concentrations of amide LAs and – most importantly – explores 
this pathway further downstream, linking the interference with this particular pathway 
to the invasion of malignant cells.  
Although determined entirely in vitro, the current study therefore provides new 
and significant insight into a potential mechanism by which amide-LAs might 
attenuate metastasis.  
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Table 1. Inhibitory properties of lidocaine and ropivacaine on TNFα-induced MMP-9 secretion by NCI-H838 lung 
adenocarcinoma cells. IC50 = half maximal inhibitory concentration; CI = confidence interval  
 
Drug IC50 [M] (95% CI) Bottom (95% CI) Top (95% CI) 
Lidocaine 3.291 x 10-6 (1.358 x 10-6 – 7.978 x 10-6) 37.62 (25.5 – 49.74) 114.0 (103.3 – 124.7) 
Ropivacaine 1.521 x 10-10 (4.155 x 10-11 – 5.57 x 10-10) 70.15 (57.72 – 82.58) 126.9 (115.3 – 138.5) 
  
Figure legends 
Figure 1: Summary of proposed mechanism by which amide-linked local 
anaesthetics inhibit cancer cell invasion and metastasis.  
As demonstrated previously, local anaesthetics (LA) block tumour necrosis 
factor α (TNFα)-induced activation of Src tyrosine protein kinase (Src) by inhibiting 
signal propogation downstream of TNF receptor 1 (TNF-R1)7 8. Through this 
mechanism, amide-linked LAs indirectly prevent activation of Akt kinase (Akt), 
phosphorylation of caveolin-1, as well as activation of focal adhesion kinase (FAK). 
These signalling steps are crucial during metastasis, as they promote cancer cell 
migration by regulating the cytoskeleton and are necessary for the secretion of 
matrix-metalloproteinases (MMP), thus enabling the cells to break up the basal 
lamina and the extracellular matrix (ECM) and further invade into the surrounding 
tissue. 
 
Figure 2. Lidocaine and ropivacaine inhibit the activation of Akt and focal 
adhesion kinase (FAK) in NCI-H838 human lung adenocarcinoma cells 
(A.) Representative Western blots of Akt phosphorylated at threonine 308 
(pT308 Akt, row 1), total Akt (row 2), and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH, row 3) after treatment with either (i.) lidocaine or (ii.) 
ropivacaine (1 nM – 100 µM) for 20 minutes in absence (A.) or presence (B.) of 
treatment with tumour necrosis factor α (TNFα) (C.) Quantitative analysis of 
densitometry of Western blots showing the ratio of pT308 Akt over total Akt in NCI-
H838 cells treated with (i.) lidocaine or (ii.) ropivacaine compared to untreated cells 
(set as 1.0, dashed line) in absence (blue bars) or presence (green bars) of TNFα 
(20 ng ml-1). Data shown are mean ± SD (n=10 for lidocaine; n=7 for ropivacaine; 
  
*p<0.05 compared to TNFα alone. (D.) Representative Western blots of FAK 
phosphorylated at tyrosine 397 (pY397 FAK, row 1), total FAK (row 2), and GAPDH 
(row 3) after treatment with either (i.) lidocaine or (ii.) ropivacaine (1 nM – 100 µM) 
alone for 20 minutes, or (E.) after treatment with TNFα in absence or presence of (i.) 
ropivacaine or (ii.) lidocaine (1 nM – 100 µM) for 20 minutes. (F.) Quantitative 
analysis of densitometry of Western blots showing the ratio of pY397 FAK over total 
FAK in NCI-H838 cells treated with (i.) lidocaine or (ii.) ropivacaine compared to 
untreated cells (set as 1.0, dashed line) in absence (blue bars) or presence (green 
bars) of TNFα (20 ng ml-1). Data shown are mean ± SD (n=8 for lidocaine, n=7 for 
ropivacaine; *p<0.05 compared to TNFα alone.  
 
Figure 3. Lidocaine and ropivacaine attenuate the phosphorylation of caveolin-
1 in NCI-H838 human lung adenocarcinoma cells 
Representative Western blots of caveolin-1 (Cav-1) phosphorylated at 
tyrosine 14 (pY14 Cav-1, row 1), total Cav-1 (row 2), and either (i.) β-actin or (ii.) 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, row 3 respectively) after 
treatment with either (i.) lidocaine or (ii.) ropivacaine (1 nM – 100 µM) alone for 20 
minutes (A.), or following (B.) treatment with TNFα in absence or presence of (i.) 
ropivacaine or (ii.) lidocaine (1 nM – 100 µM) for 20 minutes. (C.) Quantitative 
analysis of densitometry of Western blots showing the ratio of pY14 Cav-1 over total 
Cav-1 in NCI-H838 cells treated with (i.) lidocaine or (ii.) ropivacaine compared to 
untreated cells (set as 1.0, dashed line) in absence (white bars) or presence (grey 
bars) of TNFα (20 ng ml-1). Data shown are mean ± SD (n=7 for lidocaine; n=8 for 
ropivacaine; *p<0.05 compared to TNFα alone.  
 
  
Figure 4. Inhibition of TNFα-induced matrix-metalloproteinase-9 (MMP-9) 
secretion and migration of NCI-H838 lung adenocarcinoma cells in vitro.  
(A.) Amount of MMP-9 (in pg normalized to mg of cell protein content) found in cell 
culture supernatant of NCI-H838 cells treated with 100 nM Wortmannin (an inhibitor 
of phosphoinositide-3 kinase) or  5 µM FI 14 (specific FAK inhibitor) in absence (blue 
bars) or presence (green bars) of TNFα (20 ng ml-1) for 4 hours. Data shown are 
mean ± SD (n=6); *p<0.05 compared to TNFα alone. (B.) Normalized resistance of 
NCI-H838 lung cancer cell monolayers over time after electrical injury with 2.5 V at 
40,000 Hz for 10s (indicated by arrow). Treatment with either TNFα (20 ng ml-1, 
green), TNFα + lidocaine (10 µM, pink), TNFα + ropivacaine (1 µM, gold), TNFα + 
phosphoinositide-3 kinase inhibitor wortmannin (100 nM, turquoise, pre-treatment for 
30 minutes prior to addition of TNFα), TNFα + FAK inhibitor FI 14 (5 µM, orange, 
pre-treatment for 30 minutes prior to addition of TNFα), or vehicle (control, blue). 
Data shown are mean ± SD of normalized resistance. (C.) Quantification of 
normalized resistance at 3 hours. Data shown are mean ± SD; untreated cells (blue 
bar), TNFα alone (green bar), lidocaine at 10 µM (pink bar), TNFα + ropivacaine at 1 
µM (gold bar), TNFα + wortmannin (turquoise bar) and TNFα + FI 14 (orange bar); 
n=10 for control, TNFα, TNFα + ropivacaine, TNFα + lidocaine; n=8 for TNFα + 
wortmannin, TNFα + FI 14; #p<0.05 vs. untreated cells, *p<0.05 compared to TNFα 
alone. 
 
Figure 5. Inhibition of NCI-H838 lung cancer cell invasion into Matrigel® . 
Quantitative analysis of the number of invading cells found per field of view in 
DAPI stained images of the same treatment groups shown in (A.). Cells were 
  
counted semi-automatically using the ImageJ software. Data are presented as 
boxplots showing the median with 25th and 75th percentile; whiskers represent 
minimum and maximum, n=5, whereas the values for each slide were calculated as 
the mean of 8 fields of view, #p<0.05 vs. untreated cells, *p<0.05 compared to TNFα 
alone. 
 
 





